NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CRVO

CervoMed Inc

Jul 07 • 10:40AM ET

5.72

Dollar change +0.07
Percentage change 1.15	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB NBIX ACAD ITCI CYTK BTAI CORT INVA LGVN LPTX

| Held by: VTI VXF VTWO IWC IWM VTWG IWO AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.17	Insider Own	35.25%	Shs Outstand	8.70M	Perf Week	-5.54%
Market Cap	49.74M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	0.14%	Shs Float	5.63M	Perf Month	-23.60%
Enterprise Value	14.50M	PEG	-	EPS next Q	-0.59	Inst Own	26.22%	Short Float	4.83%	Perf Quarter	-49.15%
Income	-18.67M	P/S	5.34	EPS this Y	0.77%	Inst Trans	125.10%	Short Ratio	0.94	Perf Half Y	144.23%
Sales	9.31M	P/B	1.44	EPS next Y	11.52%	ROA	-80.17%	Short Interest	0.27M	Perf YTD	144.23%
Book/sh	3.98	P/C	1.41	EPS next 5Y	4.31%	ROE	-93.42%	52W High	20.63 -72.30%	Perf Year	-63.94%
Cash/sh	4.05	P/FCF	-	EPS past 3/5Y	52.23% 56.66%	ROIC	-53.91%	52W Low	1.80 217.50%	Perf 3Y	-43.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.00% 7.76%	Perf 5Y	-92.23%
Dividend TTM	-	EV/Sales	1.56	EPS Y/Y TTM	-25.82%	Oper. Margin	-224.91%	ATR (14)	0.56	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	9.78	Sales Y/Y TTM	46.26%	Profit Margin	-200.58%	RSI (14)	33.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.78	EPS Q/Q	-38.01%	SMA20	-15.89%	Beta	-0.82	Target Price	15.83
Payout	-	Debt/Eq	0.00	Sales Q/Q	-18.31%	SMA50	-27.75%	Rel Volume	1.28	Prev Close	5.65
Employees	15	LT Debt/Eq	0.00	Earnings	May 12 BMO	SMA200	-26.66%	Avg Volume	289.10K	Price	5.72
IPO	Oct 17, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	10.87% 33.62%	Trades		Volume	81,915	Change	1.15%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Upgrade	Chardan Capital Markets	Neutral → Buy	$14
Dec-17-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-11-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-11-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-10-24	Downgrade	D. Boral Capital	Buy → Hold
Dec-06-24	Initiated	ROTH MKM	Buy	$45
Dec-05-24	Initiated	H.C. Wainwright	Buy	$42
Sep-18-24	Initiated	Chardan Capital Markets	Buy	$55
Jul-26-24	Initiated	Morgan Stanley	Overweight	$35
Feb-15-24	Initiated	Canaccord Genuity	Buy	$50
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy	$1.25

Show Previous Ratings

Jun-10-25 08:00AM	CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization (GlobeNewswire)
May-12-25 09:15AM	CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.18%
08:00AM	CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-07-25 08:00AM	CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference (GlobeNewswire) -5.01%
Apr-02-25 07:00AM	Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025 (GlobeNewswire) +36.07%
02:34PM	Loading…
Mar-31-25 02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha)
Mar-25-25 08:00AM	CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD ) (GlobeNewswire) -17.37%
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
02:55AM	CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats (SeekingAlpha)
Mar-19-25 04:27PM	Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? (Insider Monkey) +23.37%
Mar-18-25 04:48AM	CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now (Insider Monkey)
Mar-17-25 08:00AM	CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) +40.53%
07:28AM	Why CervoMed Inc. (CRVO) Soared Last Week? (Insider Monkey)
Mar-14-25 11:25AM	CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program (TipRanks) +11.23%
Mar-10-25 04:05PM	CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies (GlobeNewswire) +6.31%
02:09PM	Loading…
Feb-19-25 02:09PM	Why CervoMed (CRVO) Is Advancing Today (Insider Monkey)
Jan-31-25 08:00AM	CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference (GlobeNewswire)
Jan-29-25 08:00AM	CervoMed to Present at the 8th International Lewy Body Dementia Conference (GlobeNewswire)
Dec-12-24 07:45AM	CervoMed price target lowered to $4 from $45 at Roth MKM (TipRanks)
07:00AM	CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-24 07:16AM	CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint (TipRanks) -9.72%
Dec-10-24 11:37AM	CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets (Benzinga) -78.93%
07:00AM	CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies (GlobeNewswire)
Nov-28-24 07:17AM	CervoMeds stock rises as FDA grants orphan drug status to dementia drug (Pharmaceutical Technology)
Nov-27-24 07:00AM	CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia (GlobeNewswire) +14.72%
Nov-13-24 08:00AM	CervoMed Announces Key Senior Leadership Appointments (GlobeNewswire) -5.16%
Nov-12-24 07:00AM	CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-08-24 09:55AM	CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup (GlobeNewswire)
Nov-07-24 08:30AM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 08:00AM	CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) (GlobeNewswire)
08:00AM	Loading…
Oct-29-24 08:00AM	CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference (GlobeNewswire)
Oct-15-24 08:00AM	CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Oct-04-24 04:49PM	CervoMed Ends $20 Million Stock Sales Agreement with BTIG (TipRanks) +10.30% -6.20%
Oct-02-24 08:00AM	CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-26-24 08:00AM	CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) (GlobeNewswire) +5.81%
Sep-20-24 03:37AM	CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock? (Zacks)
Aug-27-24 08:30AM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.41%
Aug-22-24 08:00AM	CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies (GlobeNewswire)
Aug-12-24 08:00AM	CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) +7.54%
Aug-04-24 09:03AM	Morgan Stanley Predicts up to ~230% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-30-24 08:00AM	CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Jul-29-24 08:00AM	CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB) (GlobeNewswire)
Jul-17-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference (GlobeNewswire) -6.73%
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire) +9.77%
Jul-11-24 08:51AM	CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024 (GlobeNewswire) +5.64%
Jul-10-24 10:52AM	CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-24-24 08:00AM	CervoMed Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-11-24 08:00AM	CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies (GlobeNewswire)
May-20-24 10:09AM	CervoMed Names William Elder CFO (MT Newswires) -18.06%
08:00AM	CervoMed to Appoint William Elder as Chief Financial Officer (GlobeNewswire)
May-15-24 09:54AM	CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-03-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire) -5.10%
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Apr-01-24 08:00AM	CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-28-24 04:05PM	CervoMed to Participate in Upcoming Investor Conferences (GlobeNewswire) +18.76%
08:30AM	CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors (GlobeNewswire)
Mar-05-24 08:00AM	CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024 (GlobeNewswire)
Feb-21-24 08:00AM	CervoMed to Participate in the BIO CEO and Investor Conference (GlobeNewswire) -7.35%
Feb-20-24 10:22AM	CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board (News Direct) -6.73%
Feb-12-24 08:00AM	CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies (GlobeNewswire) +27.12%
Feb-07-24 08:30AM	CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board (GlobeNewswire) +8.58%
07:00AM	Presenting on the Emerging Growth Conference 67 Day 2 on February 8 Register Now (GlobeNewswire)
Feb-06-24 07:00AM	Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now (GlobeNewswire)
Feb-05-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference 67 (GlobeNewswire)
Jan-10-24 07:00AM	Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream (GlobeNewswire)
Jan-09-24 07:00AM	Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now (GlobeNewswire)
Jan-05-24 08:00AM	CervoMed to Participate in the Emerging Growth Conference 66 (GlobeNewswire)
Nov-13-23 07:00AM	CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Oct-30-23 11:21AM	CRVO: New Data from Phase 2a Trial Presented at CTAD (Zacks)
Oct-25-23 02:50PM	CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies (PR Newswire) -5.44%
Oct-24-23 07:00AM	CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias (PR Newswire)
Oct-18-23 07:00AM	CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies (PR Newswire) +6.69%
Oct-05-23 07:00AM	CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference (PR Newswire)
Sep-18-23 10:40AM	CRVO: Publication in Neurology Highlights Correlation Between ptau181 Level and Response to Neflamapimod (Zacks)
Sep-05-23 07:00AM	CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire) -13.99%
Aug-21-23 08:16AM	CRVO: Initiating Coverage of CervoMed, Inc.; Phase 2b Trial in Dementia with Lewy Bodies Underway (Zacks)
Aug-15-23 04:01PM	Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma (GlobeNewswire) +7.95% +11.68%
Mar-30-23 07:00AM	EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases (GlobeNewswire) -12.78%
Dec-16-22 06:30AM	Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities (GlobeNewswire)
Dec-05-22 06:30AM	Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeScis History of Stockholder Value Destruction and Self-Dealing (GlobeNewswire) +6.89%
Dec-01-22 07:55AM	DFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23 (Zacks Small Cap Research) -5.54%
Nov-17-22 05:20PM	LifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion Pharmaceuticals (GlobeNewswire) -6.08%
Nov-14-22 04:01PM	Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.40% +14.23%
06:30AM	Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process (GlobeNewswire)
Oct-25-22 06:30AM	Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC (GlobeNewswire) +6.22%
Aug-17-22 08:52AM	DFFN: Phase 2 GBM Trial to Initiate 2H22 (Zacks Small Cap Research)
Aug-11-22 06:48PM	Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-26-22 07:30AM	Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation (GlobeNewswire) -7.31%
Jun-23-22 07:30AM	Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial (GlobeNewswire) -7.40%
May-20-22 08:10AM	DFFN: Data from Altitude Trial Expected in June 2022 (Zacks Small Cap Research)
May-18-22 07:30AM	Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer (GlobeNewswire) -6.65%
May-17-22 07:30AM	Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 04:05PM	Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.67% +12.22%
May-04-22 07:20AM	Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements (GlobeNewswire)
Apr-18-22 10:42AM	Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow (Benzinga) -34.22%
09:20AM	Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire)
Apr-11-22 07:20AM	Diffusion Pharmaceuticals Completes Dosing in Altitude Trial (GlobeNewswire)

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ELDER WILLIAM ROBERT	CFO, GC & Secretary	May 14 '25	Buy	8.46	4,233	35,811	5,500	May 14 04:11 PM
ELDER WILLIAM ROBERT	CFO & GC	Aug 27 '24	Buy	18.16	1,000	18,160	1,267	Aug 27 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRVO

CervoMed Inc

Upgrade your FINVIZ experience